Posts

Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye disease

on
Sling Therapeutics raised $123 million in a Series C financing to support the Phase 3 development of linsitinib, an oral small-molecule therapy for thyroid eye disease (TED). The company says it has already started the global Phase 3 ORBIT pivotal trial in adults with moderate to severe active TED. Linsitinib was originally developed by Astellas as a cancer drug, then licensed by Sling in 2022 for TED development. The trial is designed to study whether the drug can reduce proptosis, or eye bulging, over a 24-week treatment period. Sling says earlier midstage data showed the drug met its endpoint and had a differentiated safety profile compared with other IGF-1R treatments. The funding was led by Forbion, with participation from TPG Life Sciences Innovations and Sectoral Asset Management. Sources: Sling reels in $123M for its oral Tepezza rival in eye disease Sling Therapeutics Announces $123 Million Series C Financing to Advance Phase 3 Development of its Oral Small Mol...

Novo Nordisk Signs Up-to-$1.4B Oral Macrocycle Deal With Lilly-Backed Orbis

on

Cellares and GenomeFrontier to Evaluate Automated GF-CART01 Manufacturing

on

Novo’s rebrand: credible reset, but results will decide

on

ZBeats Receives FDA Clearance for ZBPro Diagnostic v2.0

on

Novartis to pay Sironax $125M for brain-delivery platform

on

Vera’s Strong Trutakna Data Heat Up the IgA Nephropathy Drug Race

on

Axoltis touts secondary ALS trial findings after primary endpoint miss

on

Sling raises $123M to push oral thyroid-eye-disease drug into Phase 3

on

Novartis drops VHB937 ALS program after Phase 2 failure

on

BMS and Ono sue Amgen as FDA weighs Opdivo biosimilar

on

O’Day says Gilead’s cancer and inflammation strategy has reached ‘critical mass’

on

RegCell raises $66 million to advance T-cell reprogramming

on